Return to homepagePandemic Pact

Comparing the Benefits and Harms of Medicines for Long-Term Treatment of Blood Clots -- The ALTERNATIVE Study

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $500,000

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Margaret Fang

  • Research Location

    United States of America

  • Lead Research Institution

    University of California-San Francisco

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Older adults (65 and older)

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

COVID-19 appears to affect blood clotting and may increase the risk of venous thromboembolism, or VTE. VTE occurs when blood clots develop inside veins. These blood clots can cause serious health problems or even death among patients in the hospital. With this enhancement, the research team will compare the risk of VTE for patients in the hospital with and without COVID-19. The team will also look at how the risk of VTE may differ for certain groups of patients. These groups include older adults, men, patients who've had VTE before, and patients with severe COVID-19.